Clinical Trials Browser

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02496208 2026-03-18

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03478462 2026-03-18

CLOVER-2

Phase 1 Active not recruiting

30 enrolled

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04491942 2026-03-18

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Phase 1 Active not recruiting

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

8 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

CLOVER-2

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

Study of DF6215 in Patients With Advanced Solid Tumors

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

STRIKE-001

A Phase 1 Study of the Safety and Tolerability of CTX-10726

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

COAXIN

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

ARX517

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

TAR-210

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

STELLAR-002

DK222 Study at Hopkins

A Study of GEN1106 in Participants With Solid Tumors

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

MK-5684-005

OMNIRAY

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer